AU2012252437B2 - Molecular markers in prostate cancer - Google Patents

Molecular markers in prostate cancer Download PDF

Info

Publication number
AU2012252437B2
AU2012252437B2 AU2012252437A AU2012252437A AU2012252437B2 AU 2012252437 B2 AU2012252437 B2 AU 2012252437B2 AU 2012252437 A AU2012252437 A AU 2012252437A AU 2012252437 A AU2012252437 A AU 2012252437A AU 2012252437 B2 AU2012252437 B2 AU 2012252437B2
Authority
AU
Australia
Prior art keywords
prostate cancer
expression
prca
prostate
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012252437A
Other languages
English (en)
Other versions
AU2012252437A1 (en
Inventor
Franciscus Petrus Smit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MDxHealth Research BV
Original Assignee
Noviogendix Research BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noviogendix Research BV filed Critical Noviogendix Research BV
Publication of AU2012252437A1 publication Critical patent/AU2012252437A1/en
Application granted granted Critical
Publication of AU2012252437B2 publication Critical patent/AU2012252437B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2012252437A 2011-05-12 2012-05-09 Molecular markers in prostate cancer Ceased AU2012252437B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2011/057716 2011-05-12
EP2011057716 2011-05-12
PCT/EP2012/058502 WO2012152811A1 (fr) 2011-05-12 2012-05-09 Marqueurs moléculaires du cancer de la prostate

Publications (2)

Publication Number Publication Date
AU2012252437A1 AU2012252437A1 (en) 2013-11-28
AU2012252437B2 true AU2012252437B2 (en) 2017-05-18

Family

ID=46052752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012252437A Ceased AU2012252437B2 (en) 2011-05-12 2012-05-09 Molecular markers in prostate cancer

Country Status (5)

Country Link
US (3) US20140073535A1 (fr)
AU (1) AU2012252437B2 (fr)
CA (1) CA2835730C (fr)
ES (1) ES2663069T3 (fr)
WO (1) WO2012152811A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108220443A (zh) * 2018-01-31 2018-06-29 北京泱深生物信息技术有限公司 Cgref1作为标志物在肾透明细胞癌诊疗中的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
EP3812469A1 (fr) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Signatures géniques pour le pronostic du cancer
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
WO2013064636A1 (fr) * 2011-11-04 2013-05-10 Noviogendix Research B.V. Combinaisons de marqueurs moléculaires dans le cancer de la prostate fournissant un outil de diagnostic ayant une sensibilité/spécificité améliorée
EP2920322B1 (fr) 2012-11-16 2023-01-11 Myriad Genetics, Inc. Signatures génétiques utilisées en vue du pronostic d'un cancer
CN105861692A (zh) * 2013-06-24 2016-08-17 复旦大学附属肿瘤医院 研究前列腺癌复发和转移的方法
AU2014308050A1 (en) * 2013-08-13 2016-03-03 Noviogendix Research B.V. Combinations of molecular markers in prostate cancer providing a diagnostic tool with improved sensitivity/specificity
WO2015070045A1 (fr) * 2013-11-08 2015-05-14 Baylor College Of Medicine Nouveaux marqueurs diagnostiques/pronostiques et cible thérapeutique pour le cancer
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
WO2015175692A1 (fr) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Signatures génétiques utilisées en vue du pronostic d'un cancer
US10329625B2 (en) 2015-11-20 2019-06-25 Mdxhealth Research B.V. Method for detecting DLX1 mRNA, HOXC6 mRNA, and KLK3 mRNA in a urine sample and predicting and treating clinically significant prostate cancer
SG10202006117QA (en) * 2016-04-21 2020-08-28 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042742A1 (fr) * 2007-09-25 2009-04-02 The Regents Of The University Of Michigan Marqueurs cancéreux dlx1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20080182865A1 (en) * 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
JP2012504397A (ja) * 2008-10-01 2012-02-23 ノヴィオジェンディクス・リサーチ・ベスローテン・フェンノートシャップ 前立腺がんにおける分子マーカー

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042742A1 (fr) * 2007-09-25 2009-04-02 The Regents Of The University Of Michigan Marqueurs cancéreux dlx1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108220443A (zh) * 2018-01-31 2018-06-29 北京泱深生物信息技术有限公司 Cgref1作为标志物在肾透明细胞癌诊疗中的应用

Also Published As

Publication number Publication date
CA2835730C (fr) 2021-06-01
CA2835730A1 (fr) 2012-11-15
AU2012252437A1 (en) 2013-11-28
US20200165684A1 (en) 2020-05-28
ES2663069T3 (es) 2018-04-11
CA3115945A1 (fr) 2012-11-15
WO2012152811A1 (fr) 2012-11-15
US20210246515A1 (en) 2021-08-12
US20140073535A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
US20210246515A1 (en) COMBINATION OF mRNA EXPRESSION LEVELS OF DLX1 AND HOXC6 IN URINE AS MOLECULAR MARKERS IN PROSTATE CANCER
AU2009299862B2 (en) Molecular markers in prostate cancer
EP3080293B1 (fr) Classification du cancer de la prostate
EP2971177B1 (fr) Compositions et procédés pour détecter et déterminer un pronostic de cancer de la prostate
WO2012152800A1 (fr) Marqueurs moléculaires dans le cancer de la prostate
EP3237640B1 (fr) Test de méthylation d'adn pour le cancer de la prostate
O'DRISCOLL et al. Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR
AU2012331104B2 (en) Combinations of molecular markers in prostate cancer providing a diagnostic tool with improved sensitivity/specificity
JP5865241B2 (ja) 肉腫の予後分子署名およびその使用
US20140106363A1 (en) Molecular markers in prostate cancer
CA3115945C (fr) Marqueurs moleculaires du cancer de la prostate
EP3348652B1 (fr) Marqueurs moléculaires du cancer de la prostate
EP2334809B1 (fr) Marqueurs moléculaires pour le cancer de la prostate
EP3033430B1 (fr) Combinaisons de marqueurs moléculaires du cancer de la prostate, permettant d'obtenir un outil de diagnostic ayant une sensibilité/spécificité améliorées
EP2773768B1 (fr) Combinaisons de marqueurs moléculaires dans le cancer de la prostate fournissant un outil de diagnostic ayant une sensibilité/spécificité améliorée
EP2707500A1 (fr) Marqueurs moléculaires dans le cancer de la prostate
Saramäki Gene copy number alterations in prostate cancer
Wu Circulating cell-free DNA methylation analysis of metastatic prostate cancer
KR20250086607A (ko) 전립선암의 진단을 위한 신규 rna 바이오마커
EP3696283B1 (fr) Marqueurs moléculaires dans le cancer de la vessie
AU2014224523A1 (en) Molecular markers in bladder cancer
Gabril et al. Molecular Testing in Prostate Cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired